Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases

Blood

Volumn 106, Issue 3, 2005, Pages 1098-1104

  Najahi Missaoui, Wided ^b   Dailey, Harry A ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; FERROCHELATASE;

ALLELE; ARTICLE; ENZYME ACTIVITY; ENZYME SYNTHESIS; ERYTHROPOIESIS; ERYTHROPOIETIC PROTOPORPHYRIA; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; MUTANT; PRIORITY JOURNAL; WILD TYPE;

EID: 23044452883     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4661     Document Type: Article

References (46)

1. Dailey HA, Dailey TA, Wu CK, et al. Ferrochelatase at the millennium: structures, mechanisms and [2Fe-2S] clusters. Cell Mol Life Sci. 2000;57: 1909-1926.
2. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol. 1994;131:751-766.
3. Thunell S, Harper P, Brun A. Porphyrins, porphyrin metabolism and porphyrias, IV: pathophysiology of erythropoietic protoporphyria-diagnosis, care and monitoring of the patient. Scand J Clin Lab Invest. 2000;60:581-604.
4. Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr. 2000;159:719-725.
5. Meerman L. Erythropoietic protoporphyria: an overview with emphasis on the liver. Scand J Gastroenterol Suppl. 2000;232:79-85.
6. Bloomer JR, Rank JM, Payne WD, et al. Follow-up after liver transplantation for protoporphyric liver disease. Liver Transpl Surg. 1996;2:269-275.
7. Haeger-Aronsen B, Stathers G, Swahn G: Hereditary coproporphyria: study of a Swedish family. Ann Int Med. 1968;69:221-227.
8. Whatley SD, Mason NG, Khan M, et al. Autosomal recessive erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to liver disease. J Med Genet. 2000;41:e105.
9. Sarkany RP, Alexander GJ, Cox TM. Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet. 1994;343:1394-1396.
10. Goerz G, Bunselmeyer S, Bolsen K, Schurer NY. Ferrochelatase activities in patients with erythropoietic protoporphyria and their families. Br J Dermatol. 1996;134:880-885.
11. Gouya L, Deybach JC, Lamoril J, et al. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am J Hum Genet. 1996;58: 292-299.
12. Gouya L, Puy H, Lamoril J, et al. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood. 1999;93:2105-2110.
13. Wu CK, Dailey HA, Rose JP, Burden A, Sellers VM, Wang BC. The 2.0 Å structure of human ferrochelatase, the terminal enzyme of heme biosynthesis. Nat Struct Biol. 2001;8:156-160.
14. Burden AE, Wu CK, Dailey TA, et al. Human ferrochelatase: crystallization, characterization of the [2Fe-2S] cluster and determination that the enzyme is a homodimer. Biochem Biophys Acta. 1999;1435:191-197.
15. Dailey HA. Conversion of coproporphyrinogen to protoheme in higher eukaryotes and bacteria: terminal three enzymes. In: Dailey HA, ed. Biosynthesis of Heme and Chlorophylls. New York, NY: McGraw-Hill. 1990:123-161.
16. Karr SR, Dailey HA. The synthesis of murine ferrochelatase in vitro and in vivo. Biochem J. 1988; 254:799-803.
17. Todd DJ. Clinical implications of the molecular biology of erythropoietic protoporphyria. J Eur Acad Dermatol Venereol. 1998;11:207-213.
18. Rufenacht UB, Gouya L, Schneider-Yin X, et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet. 1998; 62:1341-1352.
19. Sellers VM, Wu CK, Dailey TA, Dailey HA. Human ferrochelatase: characterization of substrate-iron binding and proton abstracting residues. Biochemistry. 2001;40:9821-9827.
20. Martinez FDM, Di Pierro ED, Biolcati G, Florelli G, Cappellini MD. Human gene mutation. Hum Genet. 2001;109:241-243.
21. Lamoril J, Boulechfar S, de Verneuil H, Grandchamp B, Nordmann Y, Deybach JC. Human erythropoietic protoporphyria: two point mutations in the ferrochelatase gene. Biochem Biophys Res Commun. 1991;181:594-599.
22. Gouya L, Schneider-Yin X, Rufenacht U, et al. Mutations in the ferrochelatase gene of four Spanish patients with erythropoietic protoporphyria. J Invest Dermatol. 1998;111:406-409.
23. Schneider-Yin X, Gouya L, Dorsey M, Rüfenacht U, Deybach JC, Ferreira GC. Mutations in the iron-sulfur cluster ligands of the human ferrochelatase lead to erythropoietic protoporphyria. Blood. 2000;96:1545-1549.
24. Brenner DA, Didier JM, Frasier F, Christensen SR, Evans GA, Dailey HA. A molecular defect In human protoporphyria. Am J Hum Genet. 1992; 50:1203-1210.
25. Dailey HA, Finnegan MG, Johnson MK. Human ferrochelatase is an iron-sulfur protein. Biochemistry. 1994;33:403-407.
26. Frustaci JM, O'Brian MR. The Escherichia coli visA gene encodes ferrochelatase, the final enzyme of the heme biosynthetic pathway. J Bacteriol. 1993;175:2154-2156.
27. Dailey HA, Dailey TA. Ferrochelatase. In: Kadish KM, Smith KM, Guillard R, eds. The Porphyrin Handbook. St Louis, MO: Elsevier Science; 2003: 93-121.
28. Zhang AS, Sheftel AD, Ponka P. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood. 2005;105:368-375.
29. Yoon T, Cowan JA. Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem. 2004;279:25943-25946.
30. Ferreira GC, Andrew T, Karr SW, Dailey HA. Organization of the terminal two enzymes of the heme biosynthetic pathway: orientation of protoporphyrinogen oxidase and evidence fora membrane complex. J Biol Chem. 1988;263:3835-3839.
31. Proulx KL, Woodard SI, Dailey HA. In situ conversion of coproporphyrinogen to heme by murine mitochondria: terminal steps of the heme biosynthetic pathway. Prot Sci. 1993;2:1092-1098.
32. Dailey HA, Sellers VM, Dailey TA. Mammalian ferrochelatase: expression and characterization of normal and two human protoporphyric ferrochelatases. J Biol Chem. 1994;269:390-395.
33. Crouse BR, Sellers VM, Finnegan MG, Dailey HA, Johnson MK. Site-directed mutagenesis and spectroscopic characterization of human ferrochelatase: identification of residues coordinating the [2Fe-2S] cluster. Biochemistry. 1996;35: 16222-16229.
34. Bottomley SS. Erythropoietic disorders involving heme biosynthesis. In: The Porphyrin Handbook. VoL 14. Kadish KM, Smith KM, Guilard R, eds. San Diego, CA: Academic Press; 2003:1-21.
35. Ponka P. Recent advances in cellular iron metabolism. J Trace Elements Exp Med. 2003;16:201-217.
36. Sadlon TJ, Dell'Oso T, Surinya KH, May BK. Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. Int J Biochem Cell Biol. 1999;31:1153-1167.
37. Baker H. Erythropoietic protoporphyria provoked by iron therapy. Proc R Soc Med. 1971;64:610-611.
38. Milligan A, Graham-Brown RA, Sarkany I, Baker H. Erythropoietic protoporphyria exacerbated by oral iron therapy. Br J Dermatol. 1988;119:63-66.
39. McClements BM, Bingham A, Callender ME, Trimble ER. Erythropoietic protoporphyria and iron therapy. Br J Dermatol. 1990;122:423-424.
40. Rothstein G, Lee R, Cartwright GE. Sideroblastic anemia with dermal photosensitivity and greatly increased erythrocyte protoporphyrin. N Engl J Med. 1969;280:587-590.
41. Romslo I, Brun A, Sandberg S, Bottomley SS, Hovding G, Talstad I. Sideroblastic anemia with markedly increased free erythrocyte protoporphyrin without dermal photosensitivity. Blood. 1982; 59:628-633.
42. Lim HW, Cooper D, Sassa S, Dosik H, Buchness MR, Soter NA. Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia. J Am Acad Dermatol. 1992;27:287-292.
43. Rademakers LH, Koningsberger JC, Sorber CW, Baart de la Faille H, Van Hattum J, Marx JJ. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest. 1993;23:130-138.
44. Aplin C, Whatley SD, Thompson P, et al. Late-onset erythropoietic porphyria caused by a chromosome 18q deletion in erythroid cells. J Invest Dermatol. 2001;117:1647-1649.
45. Najahi-Missaoui W, Wang K-F, Dailey HA. Expression and characterization of mixed heterodimeric erythropoietic protoporphyric ferrochelatases [abstract]. Blood. 2003;102:755.
46. DeLano WL. The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific; 2004.